Pharmacy Learning Centre
A call to action
Around 35% of pharmacists speak to adult patients about acute pain two-to-five times per day, according to our 2018 survey of over 1,000 members of The Royal Pharmaceutical Society. This will likely increase due to the implementation of prescribing restrictions and the current COVID-19 pandemic.
However, this survey also worryingly revealed that more than 20% of respondents would recommend co-codamol as first-line treatment for migraine, which goes against guidelines.
Pharmacy teams need to review the advice and support they currently provide, in order to demonstrate to patients that they are best placed to help them effectively manage self-limiting conditions through patient-centred self-care.
Start a new learning journey today – find out more below.
There is no proven scientific evidence preventing the use of either paracetamol or ibuprofen in treating symptoms of COVID-19. Find out more here.
Find out about the background behind our campaign and how our learning resources and articles can support your practice here.
Start a new learning journey
Do you know what the current evidence base and guidelines recommend for the management of acute pain?
How can best practice be applied to the patient?
These learning articles and resources aim to support this understanding, implement a change in behaviours and help pharmacists and their teams deliver effective patient consultations through the application of best practice.